Continuous infusion of meropenem–vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance.

Autor:	Larcher, Romaric, Laffont-Lozes, Paul, Naciri, Tayma, Bourgeois, Pierre-Marie, Gandon, Cléa, Magnan, Chloé, Pantel, Alix, Sotto, Albert
Předmět:	ANTIBIOTICS MEROPENEM BLOOD BACTERIAL proteins INTRAVENOUS therapy SEQUENCE analysis CELL culture CRITICALLY ill PATIENTS ENTEROBACTERIACEAE diseases CARBAPENEM-resistant bacteria SEPSIS KLEBSIELLA infections COMPARATIVE studies TREATMENT effectiveness DESCRIPTIVE statistics DRUG monitoring GENOMICS POSITRON emission tomography BIOTRANSFORMATION (Metabolism) COMPUTED tomography MICROBIAL sensitivity tests SYMPTOMS
Zdroj:	Infection; Dec2023, Vol. 51 Issue 6, p1835-1840, 6p
Abstrakt:	Purpose: To demonstrate the feasibility of continuous infusion of meropenem–vaborbactam to optimize the treatment of carbapenem-resistant Enterobacterales. Methods: Report of a case of a Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae bloodstream infection comfirmed by whole genome sequencing and therapeutic drug monitoring (TDM) of meropenem. Results: A patient with augmented renal clearance (ARC) went into septic shock caused by an ST11 KPC-3-producing K. pneumoniae bloodstream infection that was successfully treated with a continuous infusion of meropenem–vaborbactam at a dosage of 1 g/1 g q4h as a 4-h infusion. TDM confirmed sustained concentrations of meropenem ranging from 8 to 16 mg/L throughout the dosing interval. Conclusion: Continuous infusion of meropenem–vaborbactam was feasible. It could be appropriate for optimizing the management of critically ill patients with ARC, as it resulted in antibiotic concentrations above the minimum inhibitory concentration for susceptible carbapenem-resistant Enterobacterales (up to 8 mg/L) throughout the dosing interval. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink